Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Period	Debt/Equity
2021-12-31	0.02
2022-12-31	0.03
2023-12-31	0.11
2024-12-31	0.06

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TYRA	$36.69	-1.19%	1.01M
3
4
5

Tyra Biosciences Inc. (TYRA) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Tyra Biosciences Inc. Data in Excel

More TYRA Financial Data